The Study of add on effect of Madhusudan Vati and Arogyavardhini Vati in Prameha with special reference to Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.47552/ijam.v14i2.3302Keywords:
Ayurveda, Prameha, Type 2 Diabetes Mellitus, Madhusudhan Vati, Arogyavardhini VatiAbstract
Prameha (Diabetes mellitus) is an age long disease known from vedic period and now it is a leading lifestyle disorder. Diabetes mellitus is a group of metabolic syndromes of fat, protein and carbohydrate which is due to absolute or relative deficiency of insulin, characterized by hyperglycemia over a prolonged period with polyuria, polydipsia, and polyphagia like symptoms. The estimates in 2019 showed that 77 million individuals had diabetes in India, which is expected to rise to over 134 million by 2045. It has turned out to be the biggest “silent killer” in today’s world. This is an Open label Comparative clinical study with pre-test and post-test design where in 60 patients suffering from Prameha (type 2 DM) of either gender between the age group of 25 to 75 years were randomly selected and grouped into Group A and Group B. The 30 patients in Group A were treated with Arogyavardhini vati & Madhusudhan vati with Metformin (500 mg) and Glimepiride (1mg) BD. Group B of 30 patients were given Metformin (500mg) and Glimepiride (1 mg) for 120 days. Results obtained in subjective and objective parameters were analyzed for the statistical significance by adapting paired T test, unpaired T test, Mann-Whitney Z and Wilcoxon Signed Ranks Test Z. The study revealed that Group A was found to be more effective in bringing symptomatic relief and improving biochemical markers in the patients of Prameha.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 International Journal of Ayurvedic Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.